A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02368613
Recruitment Status : Unknown
Verified October 2016 by Daewon Pharmaceutical Co., Ltd..
Recruitment status was:  Not yet recruiting
First Posted : February 23, 2015
Last Update Posted : October 10, 2016
Information provided by (Responsible Party):
Daewon Pharmaceutical Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of hypercholesterolemia patients by conducting phase 2a. 4 groups involving placebo group, each groups are composed by 16, will be participated in this trial.

Condition or disease Intervention/treatment Phase
Hypercholesterolemia Drug: DW-3102 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Estimated Primary Completion Date : October 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: placebo group
Drug: DW-3102
Active Comparator: test1 group
DW-3102 125mg
Drug: DW-3102
Active Comparator: test2 group
DW-3102 250mg
Drug: DW-3102
Active Comparator: test3 group
DW-3102 500mg
Drug: DW-3102

Primary Outcome Measures :
  1. The change of LDL-C% [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • More than 19 years old
  • Those who meet the fasting serum lipid levels along table
  • Those who are under 350 mg/dL of TG level when fasting

Exclusion Criteria:

  • The patient of acute arterial disease
  • The patient of severe heart failure(NYHA class III or IV)
  • Within the last 6 months clinically meaningful treatment that requires that arrhythmias or cardiac conduction disorders
  • Uncontrolled hypertension ( systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg or more later)
  • Endocrine or metabolic disease patients known to affect serum lipids or lipoproteins
  • Fibromyalgia, myopathy, rhabdomyolysis, or sudden muscle pain or have in the past, such as statin (HMG CoA reductase inhibitors) in patients with muscle -related adverse drug experience of the system
  • Drug malabsorption by gastrointestinal surgery experience (but simple appendectomy and hernia surgery is excluded) or gastrointestinal disorders ( Crohn's disease , ulcers , acute or chronic pancreatitis , etc. )
  • Patients with history of malignancies including leukemia and lymphoma within the past five years
  • If severe renal impairment or in patients with impaired liver and hematological findings following the same
  • Patients who have participated in another clinical trial within the previous 30 days or Prior to the administration of at least five times the half-life of the active ingredient is not elapsed patient IND
  • Those having a known hypersensitivity to hyperlipidemia treatment
  • Patients with hypersensitivity or allergy to cruciferous plants
  • Patients with a history of drug or alcohol abuse within the last 12 months
  • Female patients of childbearing age
  • In the case of male test subjects , if the spouse does not agree with the use of childbearing age when women work , recognized contraception exclusion criteria presented in Section 15
  • Patient who are inappropriate by investigator's decision

Responsible Party: Daewon Pharmaceutical Co., Ltd. Identifier: NCT02368613     History of Changes
Other Study ID Numbers: DW-3102_201
First Posted: February 23, 2015    Key Record Dates
Last Update Posted: October 10, 2016
Last Verified: October 2016

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases